Bio-Path Holdings

Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline includes Prexigebersen, BP1002, and BP1003. The company was founded by Peter Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bio-Path Holdings reports positive Q1 results and advances key drug programs

Bio-Path Holdings (BPTH) showcased progress in key drug programs, financial stability, and global patent expansion. While facing regulatory and competitive challenges, the company is well-positioned to capitalize on opportunities in the biopharmaceutical sector. Optimism for future growth and innovation was expressed by CEO Peter Nielsen during the earnings call.

Bio-Path reports Q2 progress with prexigebersen and promising trials

Bio-Path Holdings showcased progress in clinical trials and financial management, emphasizing innovation and commitment to revolutionize cancer treatment.
While facing challenges in commercialization and market competition, the company's strong dedication to personalized medicine and promising trial results present growth opportunities.
With a focus on leveraging molecular biomarkers and advancing pipeline candidates, Bio-Path is strategically positioned to drive future success in the oncology space.

Bio-Path advances clinical trials, faces financial challenges, eyes growth

Bio-Path Holdings showcased progress in clinical trials targeting proteins in cancer and metabolic diseases, despite a net loss in Q3 2024.
The company's innovative approach and focus on treatment efficacy position it well for future growth and potential partnerships.
While facing financial challenges, Bio-Path's expansion into new therapeutic areas and optimistic outlook signal opportunities for the company.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline includes Prexigebersen, BP1001-A, BP1002, and BP1003. The company was founded by Peter H. Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.

Bio-Path Holdings Inc (NASDAQ: BPTH) shares are trading higher in Tuesday's after-hours session following the company's BP1003 data presentation at the 2022 American Association for Cancer Research Annual Meeting. Bio-Path presented a poster at the annual meeting titled .

Why Bio-Path Holdings Shares Are Rising After Hours

Preclinical Data Support BP1003 Combination Therapy to Treat Breast and Ovarian Cancers Preclinical Data Support BP1003 Combination Therapy to Treat Breast and Ovarian Cancers

Bio-Path Holdings Presents BP1003 Data at 2022 American Association for Cancer Research Annual Meeting

Seasoned Communications Leader Brings Significant Industry Expertise Seasoned Communications Leader Brings Significant Industry Expertise

Bio-Path Holdings Appoints Aline Sherwood to Board of Directors

Bio-Path Holdings Inc. (BPTH) CEO Peter Nielsen on Q4 2021 Results - Earnings Call Transcript

Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET

Bio-Path Holdings Reports Full Year 2021 Financial Results

HOUSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming poster presentation at the 2022 American Association for Cancer Research (AACR) Annual Meeting, taking place in Atlanta, GA on April 8-13, 2022.

Bio-Path Holdings to Present at the 2022 American Association for Cancer Research Annual Meeting

HOUSTON, March 04, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, March 11, 2022 at 8:30 a.m. ET to report financial results for the full year ended December 31, 2021 and to provide a business overview.

Bio-Path Holdings to Announce Full Year 2021 Financial Results on March 11, 2022

HOUSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that Peter Nielsen, Chief Executive Officer, will participate in a pre-recorded presentation at the H.C. Wainwright BioConnect 2022 Virtual Conference made available on Monday, January 10, 2022 at 7:00 a.m. ET.

Bio-Path Holdings to Present at H.C. Wainwright BioConnect 2022 Virtual Conference

Preliminary Prexigebersen Data Show Signs of Safety and Efficacy in High Risk AML Patients Preliminary Prexigebersen Data Show Signs of Safety and Efficacy in High Risk AML Patients

Bio-Path Holdings Presents Data from Ongoing Phase 2 Study of Prexigebersen at 2021 American Society of Hematology Annual Meeting

Bio-Path Holdings, Inc. (BPTH) CEO Peter Nielsen on Q3 2021 Results - Earnings Call Transcript

Bio-Path Holdings Reports Third Quarter 2021 Financial Results

HOUSTON, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, November 12, 2021 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2021 and to provide a business overview.

Bio-Path Holdings to Announce Third Quarter 2021 Financial Results on November 12, 2021

HOUSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming poster presentation at the 2021 American Society of Hematology (ASH) Annual Meeting and Exposition, taking place from December 11-14, 2021 in Atlanta, GA. In addition, ASH abstracts will appear in the November supplemental issue of Blood.

Bio-Path Holdings to Present Clinical Data at the 63rd Annual American Society of Hematology Annual Meeting

Phase 1/1b Clinical Trial to Evaluate Ability of Prexigebersen-A to Treat Patients with Solid Tumors, Including Ovarian, Endometrial, Pancreatic and Triple Negative Breast Cancer Phase 1/1b Clinical Trial to Evaluate Ability of Prexigebersen-A to Treat Patients with Solid Tumors, Including Ovarian, Endometrial, Pancreatic and Triple Negative Breast Cancer

Bio-Path Holdings Announces Clearance of Investigational New Drug Application for Phase 1/1b Clinical Trial of Prexigebersen-A in Solid Tumors

Bio-Path Holdings' (BPTH) IND application for BP1002 receives clearance from the FDA. It is set to begin a phase I/Ib study for treating AML patients.

Bio-Path (BPTH) to Begin Clinical Study on Leukemia Drug

BioPath (BPTH) stock is soaring higher on Tuesday after revealing an update from the FDA on its IND application for BP1002. The post BPTH Stock: The Good News That Has BioPath Investors Smiling Today appeared first on InvestorPlace.

BPTH Stock: The Good News That Has BioPath Investors Smiling Today

BPTH stock is shooting up this morning as the company reveals a new plan for evaluating the effectiveness of one of its drugs. The post BPTH Stock: Why Little-Known Bio-Path Holding Just Popped More Than 20% appeared first on InvestorPlace.

BPTH Stock: Why Little-Known Bio-Path Holding Just Popped More Than 20%

Bio-Path Holdings Inc (NASDAQ: BPTH) is surging higher Tuesday after the company announced the U.S Food and Drug Administration reviewed and cleared its Investigational New Drug application for BP1002 in refractory/relapsed acute myeloid leukemia patients. “AML patients that fail frontline venetoclax-based therapy have very poor prognosis with a median overall survival of less than three months and a novel treatment modality is urgently needed for such patients," said Peter Nielsen, president and CEO of Bio-Path Holdings.

Why Bio-Path Holdings Shares Are Surging Higher Today

The FDA has signed off Bio-Path Holdings Inc's (NASDAQ: BPTH) Investigational New Drug (IND) application for BP1002 in refractory/relapsed acute myeloid leukemia (AML) patients. In Phase 1/ 1b trial, six evaluable patients will be treated with BP1002 monotherapy in a standard 3+3 design, with a starting dose of 20 mg/m2.

Why Bio-Path Shares Are Moving Higher In Premarket Tuesday?

The shares of Bio-Path Holdings, Inc. (NASDAQ: BPTH) increased by over 30% pre-market. This is why it happened.

Bio-Path Holdings Shares Increase Over 30% Pre-Market: Why It Happened

Phase 1/ 1b Clinical Trial to Evaluate Ability of BP1002, Targeting Bcl-2 Protein, to Treat Refractory/Relapsed AML Patients Phase 1/ 1b Clinical Trial to Evaluate Ability of BP1002, Targeting Bcl-2 Protein, to Treat Refractory/Relapsed AML Patients

Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients

Nielsen Hlds

Bio-Path Holdings, Inc. (BPTH) CEO Peter Nielsen on Q2 2021 Results - Earnings Call Transcript

Bio-Path Holdings Reports Second Quarter 2021 Financial Results

HOUSTON, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, August 13, 2021 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2021 and to provide a business overview.

Bio-Path Holdings to Announce Second Quarter 2021 Financial Results on August 13, 2021

Moderna

vTv Therapeutics

Moderna, Inc. (NASDAQ: MRNA), Bio-Path Holdings, Inc. (NASDAQ: BPTH) and vTv Therapeutics Inc. (NASDAQ: VTVT) are among the biggest biotech movers Tuesday. Moderna Gains On Additional EU Orders: Moderna announced that the European Commission has purchased an additional 150 million doses of COVID-19 vaccine.

News for Bio-Path Holdings Stock (BPTH)